Surrozen Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing multispecific antibody therapies targeting Wnt, VEGF, and IL-6 pathways for retinal vascular diseases, with SZN-8141 leading and an IND planned for 2026. Manufacturing is at commercial scale, and recent financing supports clinical development. The approach aims for superior retinal drying and leverages growing strategic interest in ophthalmology.
-
The discussion highlighted the promise of Wnt pathway-targeted therapies for retinal vascular diseases, with lead molecules advancing toward IND in 2026 and a strong competitive and IP position. Financial health is robust, supported by recent fundraising and partnerships.
Fiscal Year 2025
-
Plans include a 2026 IND for a multifunctional ophthalmology antibody targeting DME and wet AMD, with a focus on bispecific and trispecific agents that combine Wnt agonism, VEGF, and IL-6 inhibition. Preclinical data show synergy, and retinal drying is prioritized as the key clinical endpoint.
-
The company is advancing bispecific and trispecific antibody therapies for retinal diseases, leveraging Wnt, VEGF, and IL-6 pathways for additive and potentially synergistic effects. IND filing for the lead program is planned for 2026, with strong financial backing to support development.
-
Wnt pathway activation is being advanced for retinal diseases, with lead molecules 8141 and 8143 targeting DME and wet AMD. Preclinical data show synergy with VEGF and IL-6 inhibition, and IND filing for 8141 is planned for 2026. Strong IP, recent financing, and competitive readouts from Merck are key near-term factors.
-
Innovative bispecific antibodies targeting the Wnt pathway show promise for treating major retinal diseases, with preclinical data indicating superior vessel normalization and potential for improved visual outcomes. Lead candidates are set for clinical entry in 2026.
-
The discussion highlighted a strategic pivot to ophthalmology, leveraging proprietary Wnt pathway technology and strong IP to develop multitargeted therapies for retinal diseases. Lead assets aim for improved efficacy and durability, supported by robust financing and preclinical data.
-
Wnt pathway modulation is driving innovation in ophthalmology, with a robust antibody pipeline targeting major retinal and corneal diseases. Preclinical data show superior efficacy to current therapies, and clinical milestones are anticipated in 2025–2026.
Fiscal Year 2024
-
Lead asset SZN-043 for severe alcohol-associated hepatitis is advancing through phase I-B trials, showing safety and efficacy signals, with key interim and full data readouts expected in 2025. Ophthalmology pipeline prioritizes Frizzled-4 VEGF, and partnerships and milestones provide financial runway.
-
The company leverages tissue-specific Wnt pathway modulation for regenerative therapies, with SZN-043 showing early safety and efficacy in severe alcoholic hepatitis and SZN-413 advancing in ophthalmology through a major partnership. Key regulatory and clinical milestones are anticipated in the coming months.